Welcome to our dedicated page for Sharps Technology news (Ticker: STSS), a resource for investors and traders seeking the latest updates and insights on Sharps Technology stock.
Sharps Technology Inc. (NASDAQ: STSS) is an innovative medical device and pharmaceutical packaging company specializing in the development and manufacturing of ultra-low waste, smart safety syringes. The company’s product lines, which include Sharps Provensa, SecurGard, and SoloGard, are designed to eliminate potentially infectious needlestick injuries and reduce waste, making drug delivery safer and more efficient.
Sharps Technology, headquartered in New York, operates a state-of-the-art manufacturing facility in Hungary and has plans to expand its operations in the United States. The company recently entered into a significant partnership with Roncadelle Operations, an Italian-based leader in the development of drug delivery devices. This partnership aims to broaden Sharps' market reach into Europe, the Middle East, Africa, and Asia-Pacific regions while allowing Roncadelle to penetrate the North and Latin American markets. The companies will collaboratively sell and distribute each other’s products, including prefilled syringes, needle guard systems, auto-injectors, and injector pen devices.
One of Sharps Technology’s latest achievements includes a $200 million Sales Agreement with Nephron Pharmaceuticals, along with the acquisition of the InjectEZ syringe manufacturing facility in South Carolina. This move will make Sharps the first dedicated polymer prefillable syringe manufacturer in North America, with plans to begin product deliveries by the second quarter of 2025. The facility will produce specialized cyclic olefin copolymer (COC) prefillable syringes, addressing the growing demand for safer, more efficient drug delivery solutions.
The company’s commitment to innovation is further highlighted by its SecureGard and SoloGard syringes, which feature active safety mechanisms and WHO-accredited reuse prevention measures to protect healthcare workers and patients. Sharps is also working on expanding its product line with new technologies such as prefilled syringes, needle guard systems, auto-injectors, and injector pen devices. These efforts align with the recent FDA guidelines encouraging healthcare providers to move away from Chinese-manufactured syringes due to safety concerns.
Sharps Technology is poised for significant revenue growth and market expansion, driven by its strategic partnerships, innovative products, and robust manufacturing capabilities. For more information, please visit www.sharpstechnology.com.
On April 5, 2023, RedChip Companies announced that interviews featuring BullFrog AI (NASDAQ:BFRG) and Sharps Technology (NASDAQ:STSS) will air on The RedChip Money Report on Bloomberg TV this Saturday, April 8, at 7 p.m. ET. The show reaches approximately 73 million households in the U.S.
These interviews aim to provide insights into the companies' innovative approaches and market strategies. BullFrog AI focuses on AI-driven drug development using its proprietary bfLEAP™ platform, while Sharps Technology specializes in innovative drug delivery systems and safety features in syringe technologies.
Sharps Technology (NASDAQ: STSS, STSSW) announced significant advancements in its partnership with Nephron Pharmaceuticals, aiming to launch commercial operations for specialty safety syringe systems. The company anticipates revenue generation from these syringes by Q2 2023. Sharps plans to introduce next-generation polymer-based products in Q3 2023, backed by a capital raise in February to support manufacturing. The partnership allows for increased production capacity, with potential growth to 100 million units annually by 2025. The growing demand for prefillable polymer-based syringes is highlighted as a key growth driver.
Sharps Technology, Inc. (NASDAQ: STSS, STSSW) has appointed Justin Page as Vice President of Technical Operations, enhancing its senior leadership team. With over 20 years of experience in injection molding within the medical device sector, Page will oversee engineering operations, focusing on the collaboration with Nephron Pharmaceuticals and accelerating production of 1ml and 10ml syringe systems. His role includes optimizing high-speed assembly and training for manufacturing processes at the InjectEZ facility. This strategic addition aims to support Sharps' transition to commercial operations and drive future product advancements.
Sharps Technology, Inc. announced a successful $3.8 million private placement, with Aegis Capital Corp. serving as the exclusive placement agent. The company specializes in innovative drug delivery systems, focusing on low waste and ultra-low waste syringe technologies designed to enhance safety for healthcare workers and the public. With a manufacturing facility in Hungary and a partnership with Nephron Pharmaceuticals, Sharps Technology aims to expand its U.S. manufacturing capacity. This funding aims to bolster Sharps Technology's capabilities in producing prefilled syringe systems.
Sharps Technology, Inc. (NASDAQ: STSS, STSSW) announced the successful closure of a private placement on February 3, 2023, generating approximately $3.8 million in gross proceeds. The offering involved issuing 2,248,521 units priced at $1.69 each, with each unit consisting of one share of common stock and a non-tradable warrant. Proceeds will be utilized to support the manufacturing of pre-filled specialty syringe systems in collaboration with Nephron Pharmaceuticals. The securities are not registered under the Securities Act and are exclusively available to accredited investors. Aegis Capital Corp. served as the exclusive placement agent.
Sharps Technology announced a securities purchase agreement with institutional investors, aiming to raise approximately $3.8 million to support manufacturing of pre-filled specialty syringe systems via its partnership with Nephron Pharmaceuticals. The deal involves issuing 2,248,521 units at $1.69 per unit, with a five-year warrant exercisable at $1.56. The closing date is expected around February 3, 2023. This funding is expected to enhance production capabilities, crucial for their innovative syringe products. The securities are being sold under a private placement not registered under the Securities Act.
Sharps Technology, Inc. (STSS, STSSW) has commenced its first commercial operations by shipping the Securegard product from its manufacturing facility in Hungary to Nephron Pharmaceuticals. Approximately 1.3 million units of Securegard are expected to be available by February 2023. This vial draw product features advanced safety measures and has received approvals from the FDA, WHO, and a CE Mark. CEO Robert Hayes expressed optimism about transitioning to revenue in the first half of 2023, highlighting that Securegard is just the beginning of their collaboration with Nephron, aimed at expanding innovative syringe offerings.
FAQ
What is the current stock price of Sharps Technology (STSS)?
What is the market cap of Sharps Technology (STSS)?
What products does Sharps Technology offer?
What recent partnership has Sharps Technology entered into?
What is significant about the $200 million Sales Agreement?
Where are Sharps Technology’s manufacturing facilities located?
What are Sharps Technology’s core innovations?
How does Sharps Technology contribute to healthcare safety?
What future plans does Sharps Technology have for product development?
Why is the partnership with Roncadelle Operations important?
What regulatory standards do Sharps Technology's products meet?